This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Simon, R. P. Search for Related Content PubMed Articles by Simon, R. P. Related Collections Other Stroke

(Stroke. 2007;38:613.)
© 2007 American Heart Association, Inc.

25th Princeton Conference on Cerebrovascular Disease: Preface

25th Princeton Conference on Cerebrovascular Disease

Preface

Roger P. Simon, MD, Session Chair

From the Dow Neurobiology Lab, Legacy Clinical Research and Technology Center, Portland, OR.

Correspondence to Roger P. Simon, Dow Neurobiology Lab, Legacy Clinical Research and Technology Center, 1225 NE, 2nd Ave (97232), PO box 3950, Portland, OR 97208-3950. E-mail rsimon@downeurobiology.org

An extract of the first 250 words of the full text is provided, because this article has no abstract.

The 25th Princeton Conference on Cerebrovascular Disease was held in Portland, Oregon, from May 19th to the 20th, 2006. This was the 50th year of this biannual meeting first held from January 24th to the 26th, 1954, in Princeton, New Jersey. Jim Toole recalled that the location and month of the Conference were selected to be remote enough and the weather inhospitable enough to insure maximum, continuous involvement by the participants in the meeting. The first 11 meetings were held in Princeton. Irving Wright, Professor of Clinical Medicine at Cornell University Medical School, was the Chairman of the first Conference. He had introduced the use of coumadin into medicine and directed the first major trial on oral anticoagulation (in acute myocardial infarction). Wright noted that with "considerable difficulty" he was able to find 38 physicians and scientists with a stroke background for the first meeting; "We could not find more!"¹ Participation in this conference and commitment to research in stroke no longer constitute a "difficulty". The national commitment to stroke treatment and research was summarized in the opening remarks to this 25th Princeton Conference by Story Landis, Director of the National Institute of Neurological Disorders and Stroke (NINDS).

In the tradition of the Princeton Conference both clinical and laboratory aspects of stroke were considered for presentation. The organizing committee decided on separate sessions for clinical and basic science topics. Sessions on clinical topics of Atrial Fibrillation, the potential of Basilar Artery Thrombolysis and Carotid Stenting, and New Approaches to Clinical . . . [Full Text of this Article]